Partial-onset Seizures
📧 Sign up to get email alerts when something new happens for Partial-onset Seizures.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2013-10-11FDA Approved: VIMPAT — Supplemental Application (UCB, Inc.)
FDA has approved a supplemental application for Vimpat (lacosamide) submitted by UCB, Inc., updating the product labeling. This approval upd…
-
CLINICAL_TRIALS trial_result · 2013-10-10Clinical Trial Update: Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial Seizures [Phase 3]
A Phase 3 trial evaluating eslicarbazepine acetate as add-on therapy for refractory partial seizures reported efficacy and safety results; t…
-
FDA approval · 2013-09-25FDA Approved: VIMPAT — Supplemental Application (UCB, Inc.)
The FDA approved a supplemental application for VIMPAT (lacosamide) from UCB, Inc. This supplemental approval updates the existing NDA, typi…
-
FDA approval · 2013-08-23FDA Approved: OXTELLAR XR — Supplemental Application (Supernus Pharmaceuticals, Inc.)
FDA approved a supplemental application for OXTELLAR XR (oxcarbazepine) from Supernus Pharmaceuticals, updating the product labeling.
-
CLINICAL_TRIALS trial_result · 2013-08-08Clinical Trial Update: Belgian Drug-utilization Study to Evaluate the Use of VIMPAT® as Adjunctive Treatment of Partial Onset Seizures in Subjects Aged 16 and Older
A completed clinical trial assessed lacosamide (VIMPAT) as adjunctive therapy for adults with partial-onset seizures; results were posted in…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2013-08-07FDA Approved: LEVETIRACETAM — Supplemental Application (WG Critical Care, LLC)
The FDA approved a supplemental application for levetiracetam submitted by WG Critical Care, LLC.
-
FDA approval · 2013-07-25FDA Approved: KEPPRA — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for Keppra (levetiracetam) submitted by UCB, Inc., authorizing changes to the drug's labeling.
-
FDA approval · 2013-07-25FDA Approved: KEPPRA XR — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for KEPPRA XR (levetiracetam) submitted by UCB, Inc.
-
FDA approval · 2013-06-30FDA Approved: FYCOMPA — Supplemental Application (Eisai Inc.)
The FDA approved Eisai's supplemental application for FYCOMPA (perampanel), resulting in changes to the product labeling.
-
FDA approval · 2013-06-14FDA Approved: OXTELLAR XR — Supplemental Application (Supernus Pharmaceuticals, Inc.)
The FDA approved a supplemental application for OXTELLAR XR (oxcarbazepine) from Supernus Pharmaceuticals, indicating regulatory approval to…
-
CLINICAL_TRIALS safety_alert · 2013-04-22Clinical Trial Update: Post-Authorization Safety Study to Assess the Safety of Vimpat as add-on Therapy in Patients With Partial-onset Seizures
Post-authorization safety study update assessing the safety of Vimpat (lacosamide) as add-on therapy in patients with partial-onset seizures…
-
CLINICAL_TRIALS trial_result · 2013-03-07Clinical Trial Update: An Open Label Study of L059 Intravenous (IV) in Japanese Epilepsy Subjects With Partial Onset Seizures [Phase 2]
An open-label Phase 2 study evaluating intravenous L059 in Japanese patients with epilepsy and partial onset seizures completed, with result…
-
FDA approval · 2013-02-28FDA Approved: PREGABALIN — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for pregabalin from Mylan Pharmaceuticals Inc. The approval confirms regulatory status of the generi…
-
FDA approval · 2013-02-27FDA Approved: LEVETIRACETAM — Supplemental Application (QUAGEN PHARMACEUTICALS LLC)
FDA approved a supplemental application for levetiracetam by Quagen Pharmaceuticals LLC.
-
FDA approval · 2013-02-08FDA Approved: TRILEPTAL — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for TRILEPTAL (oxcarbazepine) submitted by Novartis Pharmaceuticals Corporation. The action updates …
-
FDA approval · 2013-02-08FDA Approved: VIMPAT — Supplemental Application (UCB, Inc.)
The FDA approved a supplemental application for VIMPAT (lacosamide) submitted by UCB, Inc., expanding/updating its labeling for epilepsy.
-
FDA approval · 2013-02-08FDA Approved: VIMPAT — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for VIMPAT (lacosamide) from UCB, Inc., resulting in a labeling update/expanded use for the anticonv…
-
CLINICAL_TRIALS trial_result · 2013-01-24Clinical Trial Update: A Study of the Effectiveness, Safety, and Tolerability of Carisbamate as Add-On Therapy in Patients With Partial Onset Seizures. [Phase 3]
Phase 3 trial updating on the effectiveness, safety, and tolerability of carisbamate as add-on therapy for partial-onset seizures. The study…
-
CLINICAL_TRIALS trial_result · 2013-01-24Clinical Trial Update: Trial to Assess Optimized Dosage of Lacosamide as add-on Therapy in Patients With Partial Onset Seizure [Phase 4]
The document reports the completion of a Phase 4 trial evaluating optimized dosing of lacosamide as add-on therapy for partial onset seizure…
-
CLINICAL_TRIALS trial_result · 2013-01-23Clinical Trial Update: Effectiveness and Safety Study for RWJ-333369 as Adjunctive Therapy in Korean and Japanese Patients With Partial Onset Seizures [Phase 3]
A Phase 3 trial evaluating RWJ-333369 as adjunctive therapy for partial onset seizures in Korean and Japanese patients was terminated.
-
CLINICAL_TRIALS trial_result · 2013-01-16Clinical Trial Update: Long Term Effectiveness and Safety Study for RWJ-333369 as Adjunctive Therapy in Korean and Japanese Patients With Partial Onset Seizures [Phase 3]
This clinical trial update notes the completion of a Phase 3 long-term effectiveness and safety study of RWJ-333369 as adjunctive therapy fo…
-
CLINICAL_TRIALS trial_result · 2012-12-11Clinical Trial Update: Efficacy and Safety of Adjunctive Zonisamide in Paediatric Partial Onset Seizures (CATZ Study) [Phase 3]
Phase 3 trial assessing the efficacy and safety of adjunctive zonisamide in pediatric patients with partial-onset seizures; results were pos…
-
CLINICAL_TRIALS trial_result · 2012-11-22Clinical Trial Update: To Evaluate The Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures [Phase 3]
Phase 3 trial results update for perampanel (E2007) as adjunctive therapy in refractory partial-onset seizures, with results posted in 2012.
-
FDA approval · 2012-10-22FDA Approved: FYCOMPA — Original Application (Eisai Inc.)
FDA approved FYCOMPA (perampanel) through Eisai's original NDA for treatment of seizures associated with epilepsy, beginning with partial-on…
-
FDA approval · 2012-10-19FDA Approved: OXTELLAR XR — Original Application (Supernus Pharmaceuticals, Inc.)
FDA approves OXTELLAR XR (oxcarbazepine) from Supernus Pharmaceuticals as an original application for an extended-release formulation to tre…